menu
    • menu
    [{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"AV-001","moa":"Angiopoietin 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Vasculotide","moa":"Tie2 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vasomune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"AV-001","moa":"Tie2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"AV-001","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"AV-001","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"AnGes","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"AV-001","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ AnGes","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ AnGes"}]

    Find Clinical Drug Pipeline Developments & Deals by Vasomune Therapeutics

    Menu

    Vasomune Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : AnGes

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vasomune and AnGes Progress Phase 2a Trial Of AV-001 with High-Dose Cohort

                            Details : AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor is being investigated for the treatment of acute respiratory distress syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            December 03, 2024

                            Lead Product(s) : AV-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : AnGes

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track To Vasomune's AV-001 Novel Investigational Medicine

                            Details : AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor is being investigated for the treatment of acute respiratory distress syndrome.

                            Product Name : AV-001

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            May 28, 2024

                            Lead Product(s) : AV-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-00...

                            Details : AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature.

                            Product Name : AV-001

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            November 14, 2023

                            Lead Product(s) : AV-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy

                            Details : It analysed the safety, tolerability and pharmacokinetics of AV-001 following administration of single-ascending and multiple-ascending doses up to 56µg/kg a day for seven consecutive days.

                            Product Name : AV-001

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            March 25, 2021

                            Lead Product(s) : AV-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vasculotide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vasomune Announces FDA Allowance of IND Application For AV-001 for the Treatment of Hospitalized Patients with...

                            Details : U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for AV-001, a Tie2 tyrosine kinase receptor agonist, as a potential treatment for hospitalized patients diagnosed with moderate-to-severe COVID-19 disease.

                            Product Name : AV-001

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            November 12, 2020

                            Lead Product(s) : Vasculotide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Vasomune Therapeutics

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-001

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : US Department of Defense

                            Deal Size : $2.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001

                            Details : Funding will support the development AV-001 for the treatment of COVID-19-associated acute lung injury and acute respiratory distress syndrome (ARDS).

                            Product Name : AV-001

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            August 18, 2020

                            Lead Product(s) : AV-001

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : US Department of Defense

                            Deal Size : $2.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth